Calcium influx through the voltage-dependent L-type calcium channel (Ca V 1.2) rapidly increases in the heart during "fight or flight" through activation of the β-adrenergic and protein kinase A (PKA) signaling pathway. The precise molecular mechanisms of β-adrenergic activation of cardiac Ca V 1.2, however, are incompletely known, but are presumed to require phosphorylation of residues in α 1C and C-terminal proteolytic cleavage of the α 1C subunit. We generated transgenic mice expressing an α 1C with alanine substitutions of all conserved serine or threonine, which is predicted to be a potential PKA phosphorylation site by at least one prediction tool, while sparing the residues previously shown to be phosphorylated but shown individually not to be required for β-adrenergic regulation of Ca V 1.2 current (17-mutant). A second line included these 17 putative sites plus the five previously identified phosphoregulatory sites (22-mutant), thus allowing us to query whether regulation requires their contribution in combination. We determined that acute β-adrenergic regulation does not require any combination of potential PKA phosphorylation sites conserved in human, guinea pig, rabbit, rat, and mouse α 1C subunits. We separately generated transgenic mice with inducible expression of proteolytic-resistant α 1C . Prevention of C-terminal cleavage did not alter β-adrenergic stimulation of Ca V 1.2 in the heart. These studies definitively rule out a role for all conserved consensus PKA phosphorylation sites in α 1C in β-adrenergic stimulation of Ca V 1.2, and show that phosphoregulatory sites on α 1C are not redundant and do not each fractionally contribute to the net stimulatory effect of β-adrenergic stimulation. Further, proteolytic cleavage of α 1C is not required for β-adrenergic stimulation of Ca V 1.2.
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calcium channels | adrenergic | phosphorylation | heart | transgenic mice C a 2+ influx through the cardiac voltage-dependent L-type calcium channel (Ca v 1.2) initiates excitation-contraction coupling. As part of the "fight-or-flight" response, β-adrenergic agonists signaling through the protein kinase A (PKA) pathway rapidly enhance Ca 2+ current by increasing the mean open time (mode 2 gating) and open probability of Ca V 1.2 channels (1). The molecular mechanisms of this fundamental regulatory process remain unknown despite decades of investigation, although it is well-established that cAMP-PKA-mediated phosphorylation is a fundamental event (2) (3) (4) . PKA phosphorylation of Ser 1928 in the cardiac α 1C subunit was initially proposed to be required for adrenergic modulation (5), but this was ruled out by expression, using adenovirus or knock-in strategies, of an α 1C subunit with substitution of Ser 1928 by Ala (6, 7 (11) are also nonessential (6, 8, 12) . Thus, Ca V 1.2 residues previously identified as PKA targets by standard biochemical methodologies, including mass spectrometry and site-directed mutagenesis, are not essential for the rapid β-adrenergic stimulation of Ca V 1.2 in the heart.
The failure to identify a single site as essential for the acute β-adrenergic modulation of Ca V 1.2 led us to propose several possible explanations for these findings: (i) that the phosphorylation of any one of several α 1C residues can induce the adrenergic stimulation of Ca V 1.2 current (redundancy), (ii) that each phosphorylated residue contributes a small fraction of the total effect, and/or (iii) that the critical PKA phosphorylation sites in α 1C have not yet been identified. To test these hypotheses, we replaced with Ala all consensus intracellular PKA phosphorylation sites in α 1C that are conserved in the rabbit, human, guinea pig, mouse, and rat and determined whether elimination of PKA phosphorylation sites in α 1C blocked Ca V 1.2's responsiveness to adrenergic modulation in cardiomyocytes.
Significance
Calcium influx through the cardiac voltage-dependent L-type calcium channel (Ca V 1.2) increases during "fight or flight" through activation of the β-adrenergic and protein kinase A (PKA) signaling pathway. None of the previously identified sites in the α 1C subunit, each painstakingly and singly investigated, were shown to be required for adrenergic modulation of Ca V 1.2. Our approach allowed an unprecedented and massive increase in throughput, because we mutated many potential PKA phosphorylation sites throughout α 1C . By creating transgenic mice expressing either α 1C with alanines substituted for all conserved consensus PKA phosphorylation sites or, separately, α 1C without C-terminal proteolytic cleavage, our paradigm-shifting results show that acute β-adrenergic regulation of Ca V 1.2 does not require phosphorylation of any conserved Ser/Thr of α 1C or the proteolytic cleavage of the C terminus of α 1C .
In addition to phosphorylation by PKA, proteolytic cleavage of the α 1C C terminus, occurring in greater than 80% of cardiac Ca V 1.2 channels, has been posited to play an essential role in adrenergic regulation of Ca V 1.2. Specifically, cleavage is proposed to set the basal Ca V 1.2 activity, which is then augmented by adrenergic stimulation (5, 9, (13) (14) (15) (16) (17) (18) (10) , cleavage likely occurs in this general region based upon the observed molecular weight of the truncated α 1C (Fig. 1A) , which is still present when NNAN is deleted. Although the protease responsible for cleavage of α 1C is not known, it was speculated to be calpain-like (13, 15, 17, 19) , and a conserved motif rich in Pro, Glu, Ser, and Thr (PEST), which can serve as substrate recognition sites for calpains (20) , is just N-terminal to Ala 1800 . We hypothesized that deletion of these motifs may abrogate C-terminal proteolytic cleavage and enable us to explore the role of proteolytic cleavage in fostering β-adrenergic regulation of Ca V 1. 
Materials and Methods
Reagents. Nisoldipine and Rp-8-Br-cAMPS were purchased from Santa Cruz Biotechnology. All other chemicals were acquired from Sigma.
Animals. The α 1C transgenic constructs were generated by fusing rabbit Cacna1c cDNA (accession no. X15539) to the modified murine α-myosin heavy chain (MHC), tetracycline-inducible promoter ("responder" line) vector (a gift of Jeffrey Robbins and Jeffrey Molkentin, University of Cincinnati, Cincinnati) (21, 22) . The α 1C subunit was engineered to be dihydropyridine (DHP)-insensitive with the substitutions T1066Y and Q1070M (23, 24) . These mice were bred with cardiac-specific (αMHC) doxycycline-regulated, codon-optimized reverse transcriptional transactivator ( Immunoblots and Immunofluorescence. Cardiac lysates from 8-to 12-wk-old doxycycline-fed transgenic mice were prepared as described (10) . Proteins were size-fractionated, transferred to nitrocellulose membranes, and probed with anti-FLAG antibody (Sigma), anti-α 1C (10) , and antitubulin (Santa Cruz Biotechnology) antibodies. Detection was performed with a CCD camera (Carestream Imaging), and ImageQuant software was used for quantification. Isolated cardiomyocytes were fixed for 15 min in 4% paraformaldehyde, and indirect immunofluorescence performed using a 1:200 rabbit anti-FLAG antibody and 1:200 FITC-labeled goat-anti-rabbit antibody (Sigma). Images were acquired using a confocal microscope.
Cellular Electrophysiology. Membrane currents were measured by the wholecell patch-clamp method using a MultiClamp 700B amplifier and pCLAMP10 software (Molecular Devices) as described elsewhere (10) . The pipette solution contained 40 mM CsCl, 90 mM Cs gluconate, 10 mM 1,2-bis(o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid (BAPTA), 1 mM MgCl 2 , 4 mM Mg-ATP, 2 mM CaCl 2 , and 10 mm Hepes, adjusted to pH 7.2 with CsOH. After the isolated cardiomyocytes were adequately buffered with 10 mM BAPTA in the internal solution, the isolated cardiomyocytes (26) were superfused with 140 mM tetraethylammonium-Cl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, and 10 mM Hepes, adjusted to pH 7.4 with CsOH. Pipette series resistances were usually <1 MΩ after 60% compensation. Leak currents and capacitance transients were subtracted by a P/4 protocol. To measure Ca 2+ peak currents, the cell membrane potential was held at −50 mV and stepped to +10 mV for 350 ms every 10 s. To evaluate the current-voltage (I-V) relationship for Ca 2+ currents, the same protocol was repeated with steps between −40 mV and +60 mV in 10-mV increments. All experiments were performed at room temperature: 22 ± 1°C. For I-V curves, we used a Boltzmann distribution:
, where G max is maximal conductance, E rev is reversal potential, V mid is the midpoint, and k is the slope factor.
Fractional Shortening. Freshly isolated myocytes were superfused with Tyrode's solution containing 1.0 mM CaCl 2 and 300 nM nisoldipine. Myocytes were field-stimulated at 1 Hz. Fractional shortening of sarcomere length was measured using the SarcLen module of Ionoptix.
Statistical Analysis. Results are presented as mean ± SEM. For multiple group comparisons, one-way ANOVA, followed by Tukey's post hoc test, was performed. For comparisons between two groups, an unpaired Student's t test was used. Statistical analyses were performed using Prism 6 (Graphpad Software). Differences were considered statistically significant at values of P < 0.05. DTESPS, is also shown. Solid red circles represent some of the putative PKA phosphorylation sites. (B) Putative PKA phosphorylation sites in rabbit α 1C . Residues in red are predicted phosphorylation sites and were mutated to Ala in the 17-mutant or 22-mutant transgenic mice. Ser and Thr, shown in blue, although not predicted to be phosphorylated residues, were mutated to Ala. Conserved indicates conserved in the human, guinea pig, rabbit, rat, and mouse. Predicted indicates predicted by at least one of the prediction tools, protein kinase A phosphorylation sites using the simplified kinase binding model (pKaPS), Disorder-Enhanced Phosphorylation Sites Predictor (DISPHOS), GPS, NetPhos, and Scansite. The borderline indicates within the "twilight" zone of pKaPS (31) . (C) Schematic representation of the binary transgene system. The αMHC-rtTA is the standard cardiac-specific reverse tetracycline-controlled transactivator system. The αMHC MOD construct is a modified αMHC promoter containing the tet operon (tetO) for regulated expression of FLAG-tagged DHP-resistant (DHP*) α 1C .
Results
Generation of Inducible, Cardiac-Specific PKA Phosphorylation Site Mutant Mice. The optimal PKA phosphorylation motif is a tetrapeptide with Arg at the second and third positions (termed -2 and -3) before the phosphorylated Ser or Thr and a large hydrophobic residue immediately thereafter (R-R-X-S/T-Φ) (27) (28) (29) . The positions between -4 and -1 have a strong preference for Arg and, to a lesser extent, for His or Lys (28, 30) . We identified all potential intracellular PKA phosphorylation sites (Fig. 1B) in rabbit α 1C using both manual sequence analysis and several web-based PKA phosphorylation prediction tools, including prediction of protein kinase A phosphorylation sites using the simplified kinase binding model (pKaPS) (31), Disorder-Enhanced Phosphorylation Sites Predictor (DISPHOS) (32) , GPS (33), NetPhos (34) , and Scansite (35) . Each phosphorylation site was mutated to Ala if the Ser or Thr in rabbit α 1C was conserved in the rat, mouse, guinea pig, or human. For those conserved sites, we also mutated additional Ser and Thr within several amino acid residues C-terminal to the Arg or Lys to ensure that we fully tested each phosphoregulatory site (residues labeled blue in Fig. 1B) . If the site was not conserved among all species, and there was no alternative putative consensus PKA phosphorylation site nearby, we excluded the site from consideration. We also excluded those sites predicted to be extracellular or within the plasma membrane.
Based on the list, we generated two transgenic mice with inducible cardiomyocyte-specific expression of an N-terminal 3× FLAG-epitope-tagged DHP-resistant α 1C with Ala substitutions of all conserved Ser or Thr, either not including ("17-mutant") or including ("22-mutant") residues previously shown to be not required for β-adrenergic stimulation of Ca V 1. ) ( Fig. 1 B and C) . Several pseudo-wild-type (pWT), 17-mutant, and 22-mutant founder transgenic lines were originally created, and lines demonstrating doxycycline-induced α 1C expression after crossing with the αMHC-rtTA mice were expanded and used for this study. Because the results were consistent within each mouse line, the data were pooled for gender and founders.
Functional Studies of PKA Phosphorylation Site Mutant Mice. As in prior studies, we used a concentration of 300 nM nisoldipine, which blocked >98% of heterologously expressed WT Ca V 1.2 current in tsA-201 cells, but only blocked 34.6% of DHPinsensitive α 1C (10) . In cardiomyocytes isolated from nontransgenic mice, 300 nM nisoldipine inhibited 92.4 ± 1.6% of peak current in the absence of β-adrenergic stimulation (10) and 94.0 ± 1.2% of peak current after 200 nM isoproterenol (Fig.  S1) . Thus, when recording from cardiomyocytes expressing DHP-resistant transgenic α 1C subunits (discussed below), these data demonstrate that we have effectively blocked the endogenous channels and isolated the transgenic currents, both in the absence and presence of isoproterenol.
Transgenic mice were fed doxycycline-impregnated food overnight to induce the expression of the DHP-resistant transgenic α 1C subunits. Nisoldipine (300 nM) inhibited 51.7 ± 5.8% of peak current in cardiomyocytes isolated from doxycycline-fed pWT α 1C transgenic mice, 33.5 ± 3.9% of peak current in doxycycline-fed 17-mutant α 1C transgenic mice, and 69.5 ± 1.6% of peak current in doxycycline-fed 22-mutant α 1C mice (Fig. 2 A-C) . The midpoint potentials, derived from the Boltzmann function, for steady-state activation of the transgenic, nisoldipine-resistant 17-mutant and 22-mutant channels demonstrated a nonsignificant small leftward shift compared with pWT channels, and the slope factors for 17-mutant and 22-mutant transgenic channels were not different from pWT channels (Fig. S2 E and F) . Our interpretation of these results is that under basal conditions, the activation of the transgenic 17-mutant and 22-mutant Ca V 1.2 channels is similar to endogenous Ca V 1.2 channels.
In the cardiomyocytes isolated from pWT α 1C transgenic mice, isoproterenol increased the nisoldipine-insensitive peak current by 2 currents recorded from a series of pulses between −40 mV and +60 mV from a holding potential of −50 mV in the absence of 200 nM isoproterenol (red traces) and 3 min after isoproterenol (blue traces). The calibration was 5 picoamperes per picofarad (pA/pF) for 50 ms. Data are representative of pWT (n = 14), 17-mutant (n = 12), and 22-mutant (n = 10) I-V curves. The Boltzmann midpoint (ΔV mid ) induced by isoproterenol: pWT (−2.4 ± 0.5, P < 0.001 by paired t test, n = 12) 17-mutant (−4.5 ± 0.5, P < 0.0001 by paired t test, n = 12), and 22-mutant (−2.8 ± 0.3, P < 0.0001 by paired t test). (G) Combined bar and column scatter plot depicting the fold increase in peak current caused by isoproterenol. Bar graphs are mean ± SEM (n = 18 cardiomyocytes from eight pWT α 1C mice, n = 18 cardiomyocytes from four 17-mutant α 1C mice, and n = 44 cardiomyocytes from eight 22-mutant α 1C mice; P = 0.21 by one-way ANOVA). a mean of 1.7 ± 0.1-fold (Fig. 2 D and G) . In the cardiomyocytes isolated from the 17-mutant and 22-mutant transgenic mice, isoproterenol increased nisoldipine-resistant peak Ca V 1.2 current by a mean of 1.7 ± 0.1-fold and 1.9 ± 0.1-fold, respectively, which is nearly identical to the isoproterenol-induced augmentation of nisoldipine-resistant current in pWT α 1C transgenic cardiomyocytes (Fig. 2 E-G) . We observed a hyperpolarizing shift in the I-V curves for currents from both transgenic mutants, similar to the shift observed for pWT (Fig. 2 D-F) . Also, similar to the pWT α 1C transgenic mice, the magnitude of the isoproterenolinduced increase in the nisoldipine-resistant Ca 2+ current was inversely correlated with the basal total Ca V 1.2 current (Fig. S3) . The slopes and intercepts of the linear regression lines describing the relationship of total basal current density and response to isoproterenol were not statistically different. This inverse relationship has also been observed for endogenous Ca 2+ channels in the guinea pig and rat (12) .
Although we had eliminated the predicted PKA phosphorylation sites in α 1C, the isoproterenol-induced increased current in the cardiomyocytes isolated from the 17-mutant and 22-mutant α 1C transgenic mice was due to PKA, and not due to CaMKII, because inclusion of 10 mM BAPTA in the pipette solution should strongly and rapidly buffer [Ca 2+ ], thereby inhibiting CaMKII activity. Moreover, in the 22-mutant mice, we ablated with Ala substitutions the known CaMKII phosphorylation sites in α 1C (36) . Taken together, these results demonstrate that the adrenergic regulation of Ca V 1.2 in the heart is dependent upon neither any combination of the five previously identified phosphoregulatory sites in α 1C nor any of the additional 17 consensus PKA phosphorylation sites in α 1C that are conserved among five species.
We considered the possibility that our results were confounded by basal phosphorylation even though the isolated cells are maintained in a physiological solution without catecholamines. To address whether the Ca V 1.2 channels have basal PKA phosphorylation and whether this phosphorylation leads to increased Ca 2+ currents, we used a cell-permeable cAMP-PKA inhibitor (Rp-8-Br-cAMPS), which functions by occupying cAMP binding sites, thereby preventing dissociation and activation of the PKA holoenzyme (37) . The inhibitor can rapidly reverse isoproterenolmediated up-regulation of Ca V 1.2 of nontransgenic Ca V 1.2 channels by 96.5 ± 12.8% within 1 min (Fig. S4) , implying that the cAMP-PKA inhibitor effectively reverses any PKA-mediated increase of basal Ca V 1.2 current. These results also provide additional evidence that the effect of isoproterenol is mediated via PKA, and not CaMKII. In cardiomyocytes isolated from both pWT and the 22-mutant α 1C transgenic mice, the cAMP-PKA inhibitor had no significant inhibitory effect on nisoldipineresistant basal Ca V 1.2 currents at 1 or 2 min (Fig. 3 A-D) . These data indicate that neither endogenous nor transgenic Ca V 1.2 channels are basally activated by PKA in freshly isolated cardiomyocytes.
Proteolytic Processing of α 1C . In cardiomyocytes isolated from nontransgenic mice, native α 1C is detected as a full-length ∼240-kDa band and a cleaved ∼210-kDa band, using an anti-α 1C antibody created against an internal epitope within the intracellular loop of domains II and III (10) . To investigate the role of channel cleavage, we created two transgenic mice. In one, we deleted the PEST sequence (ΔPEST) alone. In the second, we deleted both the PEST sequence and 1794 NANINNANN 1802 (ΔPEST/PRO) (Fig. 4A ). Hearts were resected, washed of blood, and immediately frozen. The ratio of cleaved to full-length ΔPEST transgenic α 1C was 48.7 ± 3.0%, which is not significantly different from the 53.9 ± 7.1% cleavage of the pWT α 1C (mean ± SEM, P = not significant by Tukey's multiple comparison test; Fig. 4 B and C) . In contrast, the ratio of cleaved to full-length ΔPEST/PRO was 2.4 ± 0.8% (mean ± SEM, P < 0.0001 by ANOVA/Tukey's multiple comparison text compared with both pWT and ΔPEST; Fig. 4 B and C) , indicating that proteolytic cleavage requires the presence of 1794 NANINNANN 1802 .
Having generated a mutant Ca V 1.2 in cardiomyocytes for which the C terminus was resistant to proteolytic cleavage by the endogenous proteases that act on the endogenous Ca V 1.2, we then asked whether proteolytic cleavage of the C terminus was required for either trafficking or function of cardiac Ca V 1.2. We used two complementary methods to assess appropriate trafficking to the t-tubules. First, we assessed whether the transgenic myocytes contracted normally in response to Ca 2+ influx through the ΔPEST/ PRO Ca V 1.2. Cardiomyocyte contraction requires Ca 2+ influx via Ca V 1.2 in t-tubules, which triggers Ca 2+ -induced Ca 2+ release from neighboring ryanodine receptor intracellular Ca 2+ release channels and subsequent contraction. Superfusion of nisoldipine inhibited the contraction of nontransgenic cardiomyocytes to electric field stimulation at 1 Hz (Fig. 4D) , confirming the necessity of Ca V 1.2. In cardiomyocytes isolated from both pWT and ΔPEST/PRO α 1C mutant transgenic mice, field-stimulated contraction persisted in the presence of nisoldipine ( Fig. 4D ; P < 0.0001 for both pWT and ΔPEST/PRO compared with nontransgenic cardiomyocytes by ANOVA, Tukey's multiple comparison test, P = not significant between pWT and ΔPEST/PRO). Thus, the nisoldipine-resistant ΔPEST/PRO channels can trigger contraction similar to the pWT channels. Second, we observed the location of ΔPEST/PRO Ca V 1.2 channels by immunocytochemistry. Anti-FLAG antibody immunofluorescence of fixed cardiomyocytes from pWT and ΔPEST/PRO mutant transgenic mice also showed a striated pattern consistent with surface membrane distribution of expressed α 1C subunits and t-tubular localization (Fig. 4E) . No anti-FLAG antibody immunofluorescent signal was detected in cardiomyocytes isolated from nontransgenic mice, and no immunofluorescence was detected in either pWT or ΔPEST/PRO transgenic cardiomyocytes when the anti-FLAG antibody was omitted (Fig. 4E and Fig. S5 ). With this foundation, we then tested whether the absence of C-terminal cleavage affected the ability of the ΔPEST/PRO Ca V 1.2 channels to respond to isoproterenol. We measured Ca V 1.2 currents in adult cardiomyocytes from ΔPEST/PRO α 1C mutant transgenic mice. Nisoldipine (300 nM) inhibited only 41.9 ± 5.3% of peak current, implying that the transgenic channels trafficked to the membrane and were functional (Fig. 5 and Figs. S2D and S6) . The midpoint and slope of the ΔPEST/PRO α 1C channels were not different from the midpoint and slope of pWT channels (Fig. S2  E and F) . These findings imply that under basal conditions, the C-terminal proteolytic cleavage of α 1C is not required for expression and basal function of the Ca 2+ channel. In the cardiomyocytes isolated from ΔPEST/PRO α 1C transgenic mice, isoproterenol increased the nisoldipine-insensitive peak current by a mean of 1.7 ± 0.04-fold (Fig. 5 A-C) . Taken together, these results demonstrate that C-terminal proteolytic cleavage of α 1C is not required for β-adrenergic regulation of Ca V 1.2 in the heart.
Discussion
Prior studies used biochemical and mass spectrometry to identify single residues in α 1C and β 2 subunits phosphorylated by PKA as candidate targets for acute β-adrenergic regulation of Ca V 1.2 in heart. Our data show that none of those identified sites in α 1C are required for the acute fight-or-flight modulation of Ca V 1.2 by β-adrenergic agonists in the heart. For both the 17-mutant and 22-mutant mouse lines, we found that acute β-adrenergic regulation of Ca V 1.2 was not diminished, implying that Ser or Thr residues in α 1C that are common to the five species and within a consensus PKA phosphorylation site are not the functionally relevant PKA phosphorylation sites for acute modulation of Ca V 1.2 by β-adrenergic agonists. A role for the previously identified PKA phosphorylation sites within the Ca V 1.2 β 2 subunit has been excluded by several studies (6, 8, 12) . Our results suggest that the field may have been focusing on the wrong targets.
Most recently, Ser 1700 has been proposed as the critical PKA phosphorylation site in α 1C for mediating acute β-adrenergic regulation of Ca V 1.2 in the heart (9, 38) . Our studies of Ser 1700 , in isolation (10) and now in combination with other putative PKA phosphorylation sites, do not support its role as was suggested by a knock-in mouse (38) . Advantages of our approach are that expression of the mutant channels is conditional, short-term, and limited, thereby leading to fewer secondary compensatory effects, such as heart failure, which reduces normal β-adrenergic responsiveness. The potential confounders due to compensatory changes with a chronic, knock-in model are also illustrated by the decreased basal Ca V 1.2 current in cardiomyocytes isolated from an S1700A knock-in mouse, which was speculated to be secondary to reduced basal phosphorylation of Ser 1700 by PKA (38, 39) . Using a potent cAMP-PKA inhibitor that can fully reverse β-adrenergic stimulation of Ca V 1.2 when applied after isoproterenol, we demonstrate that Ca V 1.2 current is not up-regulated by cAMP-PKA-mediated pathways in unstimulated cardiomyocytes isolated from pWT α 1C mice.
Our approach also allowed us to investigate the role of proteolytic cleavage of the α 1C C terminus. Proteolytic cleavage and the subsequent assembly of the cleaved C-terminal fragment with the truncated α 1C have been proposed to play important roles in basal and adrenergic regulation of Ca V 1.2 (9, 17, 18) . Truncation of α 1C , either at Gly 1796 (immediately N-terminal to the identified protease cleavage site) or Asp 1904 caused a marked reduction in the cell surface expression of α 1C and in the Ca V 1.2 current in the heart, but not in vascular smooth muscle, leading to cardiac failure and perinatal death (18, 40) . Because the distal C terminus, after cleavage from an endogenous channel, likely remains associated with the cardiac Ca V 1.2 complex (41), expression of α 1C with a truncated distal C terminus does not mimic a physiological state. Here, we identified the proteolytic site of the cardiac Ca 2+ channels and disrupted it. This strategy enabled us to explore adrenergic regulation with the C terminus of α 1C still present but unable to be cleaved. We found that prevention of C-terminal proteolytic cleavage did not alter the expression, trafficking, basal function, or adrenergic regulation of the Ca V 1.2 in the heart. The functional effects of cleavage of α 1C remain unclear, but our studies demonstrate that proteolytic cleavage of α 1C in the heart is not required for β-adrenergic regulation of Ca V 1.2.
Taken together, our studies rule out a role for conserved PKA phosphorylation sites in α 1C contributing to acute regulation of β-adrenergic stimulation of Ca V 1.2. Moreover, our data show that these key residues are not redundant and do not each contribute combinatorially to a net stimulatory effect. Whether redundancy could exist with the Ca V 1.2 β subunit is not clear at this stage.
